Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.57 |
| ▸ | HTR1B | P28222 | 4/20 | 0.46 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15902430 | 1.00 | TAAR1 (0.57) | TAAR1SLC6A4CYP2D6SLC6A2SLC6A3 | |
| SCHEMBL5467529 | 0.85 | TAAR1 (0.55) | TAAR1SLC6A4CYP2D6SLC6A2SLC6A3 | |
| SCHEMBL715095 | 0.85 | SIGMAR1 (0.45) | TAAR1SLC6A4CYP2D6SLC6A2SLC6A3 | |
| Hydrochloric Acid SCHEMBL5301739 | 0.84 | SIGMAR1 (0.44) | TAAR1SLC6A4CYP2D6SLC6A2SLC6A3 | |
| SCHEMBL2418814 | 0.83 | SIGMAR1 (0.48) | TAAR1SLC6A4CYP2D6SLC6A2SLC6A3 | |
| SCHEMBL1740905 | 0.82 | HTR1B (0.48) | TAAR1SLC6A4CYP2D6SLC6A2SLC6A3 | |
| SCHEMBL1316541 | 0.81 | TAAR1 (0.55) | TAAR1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL5291234 | 0.81 | SIGMAR1 (0.42) | TAAR1SLC6A4CYP2D6SLC6A2SLC6A3 | |
| SCHEMBL23069137 | 0.80 | HTR1B (0.37) | TAAR1SLC6A4CYP2D6SLC6A2SLC6A3 | |
| SCHEMBL4809611 | 0.79 | SLC6A4 (0.41) | TAAR1SLC6A4CYP2D6SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 858 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12257283-B2 | Methods and compositions for use of a chemokine receptor antagonist peptide to treat addiction, substance abuse disorders or symptoms thereof | CREATIVE BIO-PEPTIDES, INC. (US) | 2025-03-25 | — | — | US | claimed |
| US-20240052418-A1 | METHOD FOR PREDICTING A SUBJECT'S RESPONSE TO SLC MODULATOR THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-02-15 | — | — | US | claimed |
| US-11850254-B2 | Tryptamine compositions for enhancing neurite outgrowth | TURTLE BEAR HOLDINGS, LLC (US) | 2023-12-26 | — | — | US | claimed |
| US-20230405028-A1 | COMPOSITIONS FOR REDUCING INFLAMMATION TO IMPROVE OR MAINTAIN MENTAL OR PHYSICAL HEALTH | GOODCAP PHARMACEUTICALS LTD (CA) | 2023-12-21 | — | — | US | claimed |
| US-11814681-B2 | Method for predicting a subjects response to SLC modulator therapy | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-11-14 | — | — | US | claimed |
| US-20230322743-A1 | NOVEL SAFRYLAMINE DERIVATIVES HAVING PRODRUG PROPERTIES | MIHKAL GMBH (CH) | 2023-10-12 | — | — | US | claimed |
| EP-4225320-A1 | COMPOSITIONS FOR REDUCING INFLAMMATION TO IMPROVE OR MAINTAIN MENTAL OR PHYSICAL HEALTH | Goodcap Pharmaceuticals Ltd. (CA) | 2023-08-16 | — | — | EP | claimed |
| EP-4211130-A1 | NOVEL SAFRYLAMINE DERIVATIVES HAVING PRODRUG PROPERTIES | COMPASS Pathfinder Limited (GB) | 2023-07-19 | — | — | EP | claimed |
| WO-2023108277-A1 | CANNABINOID AND PSYCHEDELIC FORMULATIONS COMPRISING HYDROTROPIC AGENTS | AGILE PHARMACEUTICALS SOLUTIONS INC. (CA) | 2023-06-22 | — | — | WO | claimed |
| EP-3278100-B1 | METHODS AND USES COMPRISING SOLID PHASE EXTRACTION, DERIVATIZATION WITH CROWN ETHERS, AND MASS SPECTROMETRY | TECAN SP INC (US) | 2023-06-14 | — | — | EP | claimed |
| US-20110060037-A1 | USE OF NPY Y5 RECEPTOR ANTAGONISTS FOR THE PREVENTION OF PSYCHO-STIMULANT AND OPIOID ABUSE | UNIVERSITY OF COPENHAGEN (DK) | 2011-03-10 | — | — | US | claimed |
| US-7901949-B2 | Assay | ALERE SWITZERLAND GMBH (CH) | 2011-03-08 | — | — | US | claimed |
| EP-2280703-A1 | USE OF NPY Y5 RECEPTOR ANTAGONISTS FOR THE PREVENTION OF PSYCHOSTIMULANT AND OPIOID ABUSE | Københavns Universitet (University Of Copenhagen) (DK) | 2011-02-09 | — | — | EP | claimed |
| US-20100104504-A1 | Materials and methods for diagnosis, prevention and/or treatment of stress disorders and conditions associated with abeta peptide aggregation | UNIVERSITY OF SOUTH FLORIDA (US) | 2010-04-29 | — | — | US | claimed |
| US-20100081188-A1 | APPARATUS FOR DETECTING DRUGS IN A BEVERAGE | CAMPBELL JAMES GORDON | 2010-04-01 | — | — | US | claimed |
| WO-2009112033-A1 | USE OF NPY Y5 RECEPTOR ANTAGONISTS FOR THE PREVENTION OF PSYCHOSTIMULANT AND OPIOID ABUSE | KØBENHAVNS UNIVERSITET (UNIVERSITY OF COPENHAGEN) (DK) | 2009-09-17 | — | — | WO | claimed |
| US-20080102482-A1 | Apparatus for Detecting Drugs in a Beverage | BLOOMSBURY INNOVATIONS LTD (GB) | 2008-05-01 | — | — | US | claimed |
| WO-2008026046-A1 | MORPHOLINE D3 DOPAMINE ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2008-03-06 | — | — | WO | claimed |
| EP-1714145-A1 | APPARATUS FOR DETECTING DRUGS IN A BEVERAGE | Bloomsbury Innovations Ltd. (GB) | 2006-10-25 | — | — | EP | claimed |
| WO-2005059541-A1 | APPARATUS FOR DETECTING DRUGS IN A BEVERAGE | BLOOMSBURY INNOVATIONS LTD. (GB) | 2005-06-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100104504-A1 | Materials and methods for diagnosis, prevention and/or treatment of stress disorders and conditions associated with abeta peptide aggregation | APP, BACE1, BDNF | TAAR1 96/4885SLC6A4 72/4885CYP2D6 4365/4885 |
| US-20230322743-A1 | NOVEL SAFRYLAMINE DERIVATIVES HAVING PRODRUG PROPERTIES | HTR2A, HTR2C, HTR1D | TAAR1 70/4885SLC6A4 55/4885CYP2D6 377/4885 |
| US-11850254-B2 | Tryptamine compositions for enhancing neurite outgrowth | HTR1B, HTR6, BDNF | TAAR1 128/4885SLC6A4 62/4885CYP2D6 1702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.